Posted by Michael Wonder on 08 Jul 2024
Xpovio (selinexor) approved for new indication in DLBCL in China, bringing a new treatment option to patients in the country
5 July 2024 - Results from the registrational SEARCH study in China showed that the overall response rate among the 60 Chinese patients treated with Xpovio met the study's pre-specified primary endpoint.
Antengene today announced that the China National Medical Products Administration has approved a new indication of Xpovio (selinexor) as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
